- Previous Close
609.05 - Open
620.15 - Bid --
- Ask --
- Day's Range
611.15 - 638.90 - 52 Week Range
385.45 - 646.20 - Volume
3,743,945 - Avg. Volume
2,917,026 - Market Cap (intraday)
334.687B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
166.84 - EPS (TTM)
3.72 - Earnings Date Apr 23, 2025 - Apr 28, 2025
- Forward Dividend & Yield 0.80 (0.13%)
- Ex-Dividend Date Nov 6, 2024
- 1y Target Est
526.50
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
www.lauruslabs.com6,007
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LAURUSLABS.NS
View MorePerformance Overview: LAURUSLABS.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LAURUSLABS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LAURUSLABS.NS
View MoreValuation Measures
Market Cap
328.14B
Enterprise Value
355.51B
Trailing P/E
164.16
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.29
Price/Book (mrq)
7.94
Enterprise Value/Revenue
6.79
Enterprise Value/EBITDA
39.50
Financial Highlights
Profitability and Income Statement
Profit Margin
3.80%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
52.73B
Net Income Avi to Common (ttm)
2B
Diluted EPS (ttm)
3.72
Balance Sheet and Cash Flow
Total Cash (mrq)
449.2M
Total Debt/Equity (mrq)
67.30%
Levered Free Cash Flow (ttm)
--